title: The effect of neural lesion type on botulinum toxin dosage: a retrospective chart review.
abstract: BACKGROUND
  It is difficult to compare the dosage of botulinum toxin between different neurologic conditions because of the different methods of reported dosages. Botulinum toxin is used to manage spasticity in variety of neurologic conditions, and it is important for clinicians to know whether there are differences in the dosage injected on the basis of the etiology of spasticity.
  
  
  OBJECTIVE
  To determine whether the type of neural lesion influences the dosage of botulinum toxin required to manage spasticity.
  
  
  METHODS
  Retrospective chart review.
  
  
  METHODS
  Review of patients who visited an outpatient spasticity clinic.
  
  
  METHODS
  We assessed medical charts from 99 patients with stroke, multiple sclerosis (MS), and cerebral palsy (CP) (n = 33 for each etiology). We collected information such as age, gender, weight, time of lesion, total dosage (per person, per limb, per muscle), injection location, and injections cycles.
  
  
  METHODS
  None.
  
  
  METHODS
  OnabotulinumtoxinA dose - total dose in one leg was calculated as a sum of the units of the toxin injected in all the leg muscles.
  
  
  RESULTS
  Total dose of toxin injected was 161 ± 19 (mean ± standard error of mean) in patients with stroke, 175 ± 13 in patients with CP, and 225 ± 18 in patients with MS. The total dose in the legs (normalized to body weight; units/kg) was significantly different between the 3 groups (stroke, CP, MS; P = .001). Subsequent post-hoc tests revealed that total dose in the legs of patients with MS was significantly greater (88%) than patients with stroke (P = .001). Hip adductors and hamstrings were injected most commonly in MS and CP, but toe muscles were commonly injected in patients with stroke, whereas plantar flexors were evenly injected all 3 patient groups.
  
  
  CONCLUSIONS
  In our practice, we found that treating spasticity in people with MS required the greatest dose of botulinum toxin, followed by CP and then stroke.
authors.affiliation: Upper Motorneuron Spasticity Research Program, West Park Healthcare Centre, 82 Buttonwood Ave., Toronto, Ontario, Canada M6M 2J5; Department of Physical Therapy, University of Toronto, Toronto; and Faculty of Health, York University, Toronto, Canada(∗). Electronic address: chetan.phadke@westpark.org.
authors.forename: Chetan P
authors.initials: CP
authors.lastname: Phadke
authors.affiliation: Upper Motorneuron Spasticity Research Program, West Park Healthcare Centre, Toronto, Canada(†).
authors.forename: Caitlin
authors.initials: C
authors.lastname: Davidson
authors.affiliation: Upper Motorneuron Spasticity Research Program, West Park Healthcare Centre, Toronto; and Division of Physiatry, Department of Medicine, University of Toronto, Toronto, Canada(‡).
authors.forename: Farooq
authors.initials: F
authors.lastname: Ismail
authors.affiliation: Upper Motorneuron Spasticity Research Program, West Park Healthcare Centre, Toronto; and Division of Physiatry, Department of Medicine, University of Toronto, Toronto, Canada(§).
authors.forename: Chris
authors.initials: C
authors.lastname: Boulias
mesh_terms: D065087:Acetylcholine Release Inhibitors / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D002547:Cerebral Palsy / Q000150:complications; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000209:etiology*; D012189:Retrospective Studies; D020521:Stroke / Q000150:complications
chemical_list: D065087:Acetylcholine Release Inhibitors; D019274:Botulinum Toxins, Type A